InsiderSignal.AI

InsiderSignal.ai

BFLY - Butterfly Network, Inc.

Insider Purchase by Phanstiel S. Louise (Dir)

3 Months
After Trade
Before Trade

Loading data...

Trade Summary

2 months ago, Phanstiel S. Louise, serving as Dir at Butterfly Network, Inc. (BFLY), purchased 185,261 shares at $3.08 per share, for a total transaction value of $571,160.00. Following this transaction, Phanstiel S. Louise now holds 550,766 shares of BFLY.

This purchase represents a 51.00% increase in Phanstiel S. Louise's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, December 15, 2025 and publicly disclosed via SEC Form 4 filing on Wednesday, December 17, 2025, 2 days after the trade was made.

Butterfly Network, Inc. operates in the HEALTHCARE sector, specifically within the MEDICAL DEVICES industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Phanstiel S. Louise

Dir

S. Louise Phanstiel (age 66) is an independent Director at Butterfly Network, Inc. (BFLY) since February 2021, serving as Chair of the Audit Committee and a member of the Compensation Committee. She is a certified public accountant (CPA) with a B.A. in Accounting from Golden Gate University and a CERT certification in cybersecurity oversight from Carnegie Mellon University, bringing deep expertise in healthcare, financial reporting, internal controls, and public company governance.[[1]](https://fintool.com/app/research/companies/BFLY/people/s-louise-phanstiel)[[7]](https://ir.butterflynetwork.com/governance/board-of-directors/person-details/default.aspx?ItemId=c5bc443b-1401-4e9b-9343-e22c3226fdec) Phanstiel's career highlights include senior roles at Elevance Health (formerly Anthem/WellPoint), such as President of Specialty Products, SVP Chief of Staff & Corporate Planning, and Chief Accounting Officer/Controller/CFO for subsidiaries (1996–2007), as well as Partner at PricewaterhouseCoopers specializing in insurance audits. She has chaired audit committees at Inveresk Research Group and Verastem Oncology, and currently serves as Chair of the Board at Myriad Genetics, Inc. since March 2020 (Director since September 2009). Recently, on December 17, 2025, she acquired Class A common shares of BFLY, owning approximately 550,766 shares.[[2]](https://www.tipranks.com/news/insider-trading/butterfly-network-director-makes-a-bold-stock-move-insider-trading)[[3]](https://longbridge.com/en/news/270062393)[[4]](https://www.gurufocus.com/insider/58946/s.-louise-phanstiel)[[1]](https://fintool.com/app/research/companies/BFLY/people/s-louise-phanstiel)

View full insider profile →

Trade Price

$3.08

Quantity

185,261

Total Value

$571,160.00

Shares Owned

550,766

Trade Date

Monday, December 15, 2025

69 days ago

SEC Filing Date

Wednesday, December 17, 2025

Filed 2 days after trade

HEALTHCAREMEDICAL DEVICES

About Butterfly Network, Inc.

Company Overview

No company information available
View news mentioning BFLY

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/2309776

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime